Periprocedural Myocardial Infraction: A Review Article

Authors

  • Irma Kamelia Pratiwi Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Fandy Hazzy Alfatta Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Teguh Aryanugraha Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Muhamad Bayu Aji Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Putri Annisa Kamila Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Ratna Pancasari Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Ayu Asri Devi Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Krishna Ari Nugraha Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya
  • Mohammad Saifur Rohman Dept. Jantung dan Pembuluh Darah, Fakultas Kedokteran Universitas Brawijaya

DOI:

https://doi.org/10.21776/ub.hsj.2022.003.01.3

Keywords:

periprocedural myocardial infarction, PCI, prolonged ischemia

Abstract

Percutaneous coronary intervention can be associated with several complications such as periprocedural myocardial infarction (PPMI) that was deï¬ned as an elevation of CK-MB >3 times the upper limit of the normal range in at least two blood samples with a normal range of baseline value, prolonged ischemia as demonstrated by persistent chest pain (>20 min), or new pathological Q waves seen on the electrocardiogram.

By epidemiology, periprocedural myocardial infarction was happen in about 6 – 7% patient underwent PCI and associated with adverse outcome. Therefore it is important to identify the possible factors to detect, prevent and manage this event.

References

Park D-W, Kim Y-H, Yun S-C, Ahn J-M, Lee J-Y, Kim W-J, et al. Frequency, causes, predictors, and clinical signiï¬cance of peri-procedural myocardial infarction following percutaneous coronary intervention. Eur Heart J. 2013;34:1662–9.

Lo N, Michael TT, Moin D, Patel VG, Alomar M, Papayannis A, et al. Periprocedural Myocardial Injury in Chronic Total Occlusion Percutaneous Interventions: A Systematic Cardiac Biomarker Evaluation Study. J Am Coll Cardiol Cardiovasc Interv. 2014;7(1):47–54.

Olivier CB, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, et al. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. Int J Cardiol. 2018;

Porto I, Selvanayagam JB, Van Gaal WJ, Prati F, Cheng A, Channon K NS, AP B. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analys. Circulation. 2006;114:662–669.

Abdelmeguid A, EJ T. The Myth of the Myocardial “Infarctlet†During Percutaneous Coronary Revascularization Procedures. Circulation. 1996;94(12):3369–75.

A P, BJ G, ME B, AM L, JW M, EM O. Prognostic Significance of Periprocedural Versus Spontaneously Occurring Myocardial Infarction After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes: An Analysis From the ACUITY (Acute Catheterization and Urgent Intervention T. J Am Coll cardiol. 2009;54(5):477–86.

Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. NEngl J Med. 2006;355:2203–2216.

Giugliano RP, White JA, Boden C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. NEngl J Med. 2009;360:2176–2190.

Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. NEngl J Med. 2009;360:2165–2175.

Gurm HS, Breibart Y, Vivekanathan D, et al. Preprocedural statin use is associated with a reduced hazard of postproceduralmyonecrosis in patients undergoing rotational atherectomy—a propensityadjusted analysis. Am Heart J. 2006;151:1031–1036.

Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105: 691–696.

Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2005;112:2946–2950.

Downloads

Published

2022-01-31